Hormones and Agents Affecting Hormonal Mechanism: Others
IPROL6 “Prolia injection” 60 mg/pre-filled syringe
IXGEV1 “Xgeva injection” 120 mg/ pre-filled syringe
適應症：
IPROL6：治療有骨折高風險性之停經後婦女骨質疏鬆症。說明：有骨折高風險性之停經後婦女骨質疏鬆症，包含下列任一狀況：有骨質疏鬆症骨折病史、具有多項骨折危險因子、先前接受其他骨質疏鬆症療法失敗或無法耐受其他骨質疏鬆症療法之病患。對患有骨質疏鬆症之停經後婦女，Prolia可降低脊椎、非脊椎和髖骨骨折的發生率。
IXGEV1：適用於實體腫瘤已有骨轉移之成人病患，預防發生骨骼相關事件。
Usual dose:
Adult: 60 mg SC once every 6 mon. plus calcium 1000 mg PO qd and at least 400 international units vitamin D PO qd.
Correct hypocalcemia prior to initiation of denosumab therapy. Bone metastasis, Associated with Solid Tumors – Disorder of skeletal system; Prophylaxis: 120 mg SC q4w.
Adverse effect:
Common: hypercholesterolemia, diarrhea, nausea, vomiting, arthralgia, backache, pain in limb, asthenia, headache, cystitis, nasopharyngitis, upper respiratory infection, fatigue.
Serious: endocarditis, cellulitis, dermatitis, erysipelas, rash, hypocalcemia, hypophosphatemia, pancreatitis, infectious disease, serious, aseptic necrosis of bone of jaw, dyspnea, cancer.
健保給付規範：(102/1/1、104/12/1)
限用於乳癌、前列腺癌及肺癌併有蝕骨性骨轉移之病患。